New Thermo Fisher Viral Vector CDMO site opens in Lexington

Thermo Fisher Scientific has unveiled its brand-new, ninety-million dollar, fifty-thousand square foot, viral vector contract development and manufacturing organisation (CDMO) facility, located in Lexington, Massachusetts. The company’s continuous expansion is part of a focused strategy to provide a wide-range of services to support biotech and pharma companies by advancing the commercialisation of innovative therapies through its Pharma Service businesses.

Not only will the state-of-the-art facility support the crucial development, analysis and production of viral vectors to progress new life saving gene and cell therapies worldwide, it will also create over two hundred job opportunities, boosting employment in the local area.

Thermo Fisher Scientific’s EVP, Michel Lagarde, stated: “The demand for new gene therapies has outpaced capacity, and we’re in a unique position to partner with our customers to help them accelerate development and production of medicines that will ultimately benefit patients suffering from rare diseases. We’re also excited to create 200 new jobs that support the thriving biotech industry in Massachusetts.”

Governor of Massachusetts, Charlie Baker, stated: “Thermo Fisher’s investment in both the regional economic development of the Commonwealth and its commitment to furthering STEM education for young women will well serve Massachusetts and its communities. We look forward to working together to continue to build upon and strengthen the state’s role as a global leader in innovation.”